Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ask them about financing. Last 10k says they are out of money at the end of August 2011 tomorrow!
I have e-mailed them, no reply?
BioCryst (BCRX) has the best antiviral drug for any flu. It is called peramivir (IV). FDA gave emerency use approval 2009 when the H1N1 was a scare. Should get FDA approval next year, finishing up PH 3 trials.
SSM Media Ventures Signs Acquisition Agreement With B2 Digital, Inc. Press Release Source: SSM Media Ventures, Inc. On Tuesday August 30, 2011, 5:00 am
MESA, AZ--(Marketwire -08/30/11)- B2 Digital, Inc. (Pinksheets: BTDG.PK - News) has signed an acquisition agreement with SSM Media Ventures, Inc. for the purchase of 51% of the Common Shares of B2 Digital, Inc.
On August 25, 2011, B2 Digital, Inc. (the Company) and SSM Media Ventures, Inc. (the holding Company of "Real Hip Hop Network" www.RHN.TV), signed a Merger Agreement for the purchase of 51% of the Common Stock and all unissued stock of B2 Digital. The cash offer from SSM Media Ventures, Inc. is in the amount of $2,050,011.82.
CEO & President of SSM Media Ventures, Inc., Atonn F. Muhammad, stated, "In moving forward with our subsidiary RHN launching into the Hip-Hop Markets soon, delivery of the content is critical to our overall success. Having done a share exchange with B2 Digital earlier this year has shown what B2 Digital has to offer in making many of our challenges easier to overcome. We feel we could not have found a better Company to work with by utilizing B2 Digital technology and its experience. As we reach our launch dates into the Hip-Hop Markets we now know that it will be with high quality digital performance and proven security."
The market for Hip-Hop is truly expansive and global; with an estimated 100 million fans worldwide, including 50 million in the U.S. alone, as reported by Business Week. Hip-Hop is here to stay and is the second largest selling music category, trailing only Country (for which, by comparison, there are already three dedicated cable networks). There are at least two Hip-Hop radio stations ranked among the top 10 (based on listener data) in nine of the ten largest U.S. Markets.
B2 Digital CEO & President, Paul D.H. LaBarre, stated, "All of us at B2 Digital are very excited to become involved with a cutting edge company like SSM Media Ventures and RHN. We have always placed the highest priority on creating the maximum value for our shareholders. With this in mind came our decision to focus our efforts on the Media world. Over the past several months it is proven that we are moving in the right direction. In accepting this offer from SSM Media Ventures, Inc., we at B2 Digital see a great opportunity with RHN as Mr. Muhammad and his staff advance into the Markets."
SSM Media Ventures plans to structure a series of capital infusions into B2 Digital and raise capital for future acquisitions and existing operations to include other SSM Media Ventures related properties: (Legacy Fund & (RHN) The Real Hip-Hop Network).
About B2 Digital
B2 Digital is dedicated to seeking acquisitions, mergers and joint ventures with a scope of business opportunities including the resource sector. With a merger of this type B2 Digital will become a part of one great organization, SSM Media Ventures, Inc. and RHN. For more information on B2 Digital Inc., please go to the company website at:
http://www.b2digital.us
About SSM Media Ventures
SSM Media Ventures Inc. is a premiere private equity group with a growing portfolio of companies. SSM's core concentration is in telecommunications, mobile technology, cable, internet and media. The firm currently owns controlling interest of The Real Hip-Hop Network and Legacy Fund. (www.ssm-media.com)
RHN.TV is a wholly owned subsidiary of SSM Media Ventures, Inc. Real Hip-Hop Network is a media corporation providing television programming services to diverse global markets through satellite and cable television distribution. RHN.TV is the world's first 24-hour cable network devoted to Hip-Hop Culture, Lifestyle and Music. More information on RHN can be found at:
www.rhn.tv
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result certain risk and uncertainties, including but not limited to those detailed from time to time in the Company's filings with Pink Sheets.com. All business projects are subject to numerous risk factors including changing regulations and other factors that may depend on funding and approval of government agencies.
Contact:
CONTACT:
For B2 Digital
Wyndam Media Group
Mick Bazsuly
Phone: 954-513-7911
http://finance.yahoo.com/news/SSM-Media-Ventures-Signs-iw-2329369546.html?x=0
License Agreement among Intellect and AHP MANUFACTURING BV, acting through its Wyeth Medica Ireland Branch and ELAN PHARMA INTERNATIONAL LIMITED (ANTISENILIN)
In May, 2008, we entered into a License Agreement (the “Agreement”) by and among Intellect and AHP MANUFACTURING BV, acting through its Wyeth Medica Ireland Branch, (“Wyeth”) and ELAN PHARMA INTERNATIONAL LIMITED (“Elan”) to provide Wyeth and Elan (the “Licensees”) with certain license rights under certain of our patents and patent applications (the “Licensed Patents”) relating to certain antibodies that may serve as potential therapeutic products for the treatment for Alzheimer’s Disease (the “Licensed Products”) and for the research, development, manufacture and commercialization of Licensed Products.
Pursuant to the Agreement, we granted the Licensees a co-exclusive license (co-exclusive as to each Licensee) under the Licensed Patents to research, develop, manufacture and commercialize certain Products in the Field in the Territory (all as defined in the Agreement) and a non-exclusive license under the Licensed Patents to research, develop, manufacture and commercialize certain other Licensed Products (other than Bapineuzumab Products) in the Field in the Territory. We received $1 million as of June 30, 2008 and an additional $1 million in August, 2008 pursuant to this Agreement. In addition, we are eligible to receive certain milestones and royalties based on sales of Licensed Products as set forth in the Agreement.
.
http://ir.stockpr.com/intellectns/sec-filings/content/0001144204-08-061891/v131146_10ksb-a.htm?TB_iframe=true&height=auto&width=auto&preload=false
Articles of Dissolution? from Y brd
http://www.sunbiz.org/COR/2011/0822/10676366.Tif
what is this?
Aiming at amyloid
All eyes, however, are trained on a passive immune therapy that leaves both secretase enzymes alone and goes after amyloid-ß directly. Two candidates, Eli Lilly's solanezumab and Janssen and Pfizer's bapineuzumab (originally developed by the Dublin-based company Elan), are monoclonal antibodies that work with the immune system, binding to amyloid-ß and helping to clear accumulated amyloid-ß peptides in the brain. Both are being tested in phase III trials on thousands of participants with mild-to-moderate Alzheimer's disease (see 'Chasing the dream', page S18).
But some worry that researchers are spending too much time and resources on something that might never pan out. “I think amyloid-ß is proving to be a very intractable target,” says Cummings. “The great danger to the field is that if bapineuzumab fails, some pharmaceutical companies will decide that Alzheimer's disease is too tough a target to yield stockholder value and will redirect their resources toward more tractable diseases.”
http://www.nature.com/nature/journal/v475/n7355_supp/full/475S9a.html.
I hope bapi gets approved. 5% royalites (approx)to I>L>N>S>, that's 50 million for every billion. That will finance their other drugs that are better than bapi.
http://www.intellectns.com/internal-pipeline
Regardless they still have signed royalty contracts, do you think the contracts will stand up? Why do you believe the patients will not stand? Just because it is a small penny stock company? If this was PFE's patient would you say the same?
That's ok with me. I do not want people to know. I want to get as many shares a I can at these prices.
I don't think so. I have seen sales projections from 5 to 15 billion a year. You and I could morgage our home to finanace them a year to get 1% of that. What do you think?
Should be hearing something on that anyday. I don't think that will be an problem. If bapi gets approved which looks good it will instantlay be a blockbuster. Could be the best selling ever. With ELN, JNJ, PFE and GSK and others involved do you think they will get financing?
That is one patent. They have several.
Yes they are. I am surpised you do not know this. They get royalities on Bapi and Ponezumab (PF-04360365). Any sales from PFE,JNJ and ELN. They also have a agreement with GSK and an undisclosed large phama.
http://ir.stockpr.com/intellectns/press-releases/detail/83/intellect-neurosciences-inc-grants-top-tier-global-pharmaceutical-company-license-to-certain-alzheimers-patents-and-patent-applications
.
Intellect recently announced that it has granted a royalty-bearing license to Wyeth and Elan Pharma International Ltd. (Elan) regarding patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease including a co-exclusive license to Bapineuzumab under the ANTISENILIN® patents.
.
http://ir.stockpr.com/intellectns/press-releases/detail/123/intellect-neurosciences-inc-and-medical-research-council-technology-u-k-reach-important-milestone-in-generating-an-alzheimers-therapeutic-antibody
.
I have much more DD but no time to post now.
http://www.sec.gov/Archives/edgar/data/1337905/000114420408030722/v115138_8k.htm
Wha's your opinion on the lincensee company? I>L>N>S.
Why is someone selling?
APII .185 x .19 up 31.21%
APII .185 x .19 up 31.21%
Vizzeco
Meet Our Team
Combining over 300 years of senior IT and management expertise, our team understands the importance of working ethically and openly with our clients to deliver low cost, highly effective and environmentally considerate solutions. We work hard at enabling our clients to capitalize on the significant and growing benefits of deploying Google’s cloud-based software offerings within their organization.
Andrew Greig - Founder & CEOAn “out of the box” thinker who melds an infectious enthusiasm for our planet, and all of its inhabitants, with impressive technical prowess, Andrew leads with vision and an uncanny ability to create order from chaos. Constantly challenging the status quo he makes no apologies for his voracious appetite for the kinds of change that propels humanity towards a healthier, greener future for all.
His entrepreneurial flair was made evident with his first venture which earned over one million in revenue during its first year of operations.
Elaine Turner - General ManagerEducated and trained in England, Elaine then moved to Canada to embark on her business management career. Her tenacious attention to detail helped forge strong business relationships and augmented her natural ability to lead and develop effective teams. While working at Starnix and the Linux Professional Institute, Elaine built mutually beneficial relationships with numerous global Open Source companies and organizations while honing a diverse skill set that included; global logistics; management of legal and financial functions; and day to day operations. Deeply grounded in health, wellness and spirituality, Elaine strives to create balance between her personal and professional lives.
James Howard - Board Advisor & Legal StrategistMr. Howard brings 40 years experience an incredibly diverse and deep understanding of technology and communications to the company from a legal perspective. A graduate from Queens College (B.A.) and from the Fordham University Law School (J.D.), James is an active member of the Pennsylvania State Bar Association, the National Bar Association and the Delaware Valley Computer Lawyers Group. Prior to running his own consulting practice since 1991, James filled various Information Technology and legal roles for educational institutions, government agencies and large corporations, including New York Telephone and AT&T.
Herb Phillips - Board AdvisorMr. Herb Phillipps Jr. (MBA, CMA) possesses over 35 years experience in banking, mutual funds management, investment, finance and auditing throughout Canada and the United States. As a Professional Accountant with the Certified Management Accountants of Ontario, Herb has garnered extensive experience developing and implementing business strategies that require transformational changes in order to deliver superior service solutions to satisfy customers’ needs. As the founder and CEO of HIPNET Inc. and a consultant to the AIC Group in Canada, Herb chairs the Executive Council that manages transformational projects within NCB Jamaica Limited. He is also the chief driver of the Institute of Leadership and Organizational Development (ILOD) for NCB group of companies.
Barry Walsh - Board AdvisorBarry is the founder and owner of Bevertec CST Inc. For over 28 years Bevertec has developed and implemented innovative software solutions for the financial services, manufacturing, communications, and transportation sectors, as well as all levels of government. The company focuses on providing transaction management solutions for clients in Latin America, the Middle East, Asia and Europe, as well as North America. Bevertec’s growing global client base now produces more than 90 per cent of total revenues.
John Taylor - Board AdvisorCurrently the Regional Councilor for the Town of Newmarket, Mr. Taylor has employed bachelor degrees in English and Education, a Masters degree in Canadian Studies, and a Ph.D. in Education to drive his 20 plus year career. John has a passion for challenging the status quo and has used his political skills and acumen to champion the causes of underprivileged and underserviced groups and organizations in our society, including work with First Nations Communities in the field of education, within Canada and internationally. Stints as an independent investment consultant and owner/partner in a logistics and transportation company have honed his leadership skills, while nurturing a hands-on perspective on how government and business rely on the effective performance of the other to meet their goals.
Jon “maddog” Hall - VP, Advanced Development & Industry AmbassadorA visionary and author, Masters of Computer Science graduate, with over 40 years experience in the IT and Linux community, “maddog” is the Executive Director of Linux International and serves on the boards of several companies and non-profit organizations. A well known elder statesman of the programming community and long time leader of the Open Source movement, Jon has been sought after for both speaking and consulting engagements with the governments of China, Malaysia, Brazil, South Korea and the United Nations, as well as countless local and state governments. Maddog’s passion and commitment to the free and open source software movement was honored in 2006 when he was awarded a Lifetime Recognition Award at the UK Linux and Open Source Awards.
Steven Mosher - VP, MarketingAs VP of Sales and Marketing for OpenMoko since 2007, Steve was responsible for all marketing communications, corporate planning, business development and strategic partnerships. He has led strategic initiatives, including; the development of a distribution network; the launch of Linux based mobile phones; and the building of an open community to support the OpenMoko phone. Steve’s list of accomplishments are further highlighted by; launching the very first 3D graphics add-in card for PCs – which took the #1 status position; launching the very first Mp3 player – that achieved 80% market share, and; developing and launching the first DVD drive for the PC; as well as, wireless MP3 players and a card based Personal video recorder.
George Gore - VP, SalesSince graduating from Wayne State University and earning an MBA degree from the University of Colorado, George has amassed over 33 years experience as an International Sales and Management executive within the Telco and Communications industry. While at AT&T, George worked with some of the most prestigious Global 200 level customers including Mobil Oil, Texaco, JP Morgan Bank, Merrill Lynch, Royal Bank, CIBC and Pfizer. As a certified Project Manager (PMI), George had the pleasure of leading some incredible International Network Management projects while at AT&T, including the 1994 Olympics.
Malcolm Yates - Partner ManagerMalcolm has been consistently successful in developing and delivering new business and partnerships, through leading and co-operating with diverse teams in rapidly changing, complex, global environments. As ISV Alliance Manager at Canonical (Ubuntu), Malcolm built upon his 20 years of experience in Software Marketing, Partner and Alliance Management (both technical and strategic) gained through working in European and worldwide roles with IBM and Novel. Strong vision, strategic leadership and the ability to identify and develop new opportunities and industry partnerships underpin his success.
Alexander Eisen - Security Advisor
I may hang on to this one. I posted news on a couple boards. We should have an interesting day.
apii merger Press Release Source: Action Products International, Inc. On Friday August 26, 2011, 8:29 am
NEW YORK, NY--(Marketwire -08/26/11)- Action Products International, Inc. (Pinksheets: APII.PK - News) today announced it that has entered into a Letter of Intent to merge with Google Apps® reseller VizzEco, an Ontario company. Following the merger, the two companies plan to jointly create a synergistic vertical business model designed to gain maximum benefit from leveraging the respective strengths of each company to market VizzEco's licensed Google® products and service offerings to their targeted customer market, consisting primarily of small and medium-sized businesses.
VizzEco is a licensed world-wide reseller of Google® products and services, including Google Apps® and the soon to be released Google Plus for Business® (Google+4B), which will integrate social media as a service. The VizzEco business model is designed to capitalize on the trend towards use of cloud computing services (SaaS) in replacement of PC-based software by assisting small and medium-sized businesses to take advantage of the benefits offered by SAAS. VizzEco also intends to establish a network of retail outlets to generate sales and provide customer training in order to facilitate market acceptance of Google Apps® and Google+4B services.
Safe Harbor Statement
http://finance.yahoo.com/news/Action-Products-International-iw-232537771.html?x=0
apii merger-Press Release Source: Action Products International, Inc. On Friday August 26, 2011, 8:29 am
NEW YORK, NY--(Marketwire -08/26/11)- Action Products International, Inc. (Pinksheets: APII.PK - News) today announced it that has entered into a Letter of Intent to merge with Google Apps® reseller VizzEco, an Ontario company. Following the merger, the two companies plan to jointly create a synergistic vertical business model designed to gain maximum benefit from leveraging the respective strengths of each company to market VizzEco's licensed Google® products and service offerings to their targeted customer market, consisting primarily of small and medium-sized businesses.
VizzEco is a licensed world-wide reseller of Google® products and services, including Google Apps® and the soon to be released Google Plus for Business® (Google+4B), which will integrate social media as a service. The VizzEco business model is designed to capitalize on the trend towards use of cloud computing services (SaaS) in replacement of PC-based software by assisting small and medium-sized businesses to take advantage of the benefits offered by SAAS. VizzEco also intends to establish a network of retail outlets to generate sales and provide customer training in order to facilitate market acceptance of Google Apps® and Google+4B services.
Safe Harbor Statement
http://finance.yahoo.com/news/Action-Products-International-iw-232537771.html?x=0
apii merger Press Release Source: Action Products International, Inc. On Friday August 26, 2011, 8:29 am
NEW YORK, NY--(Marketwire -08/26/11)- Action Products International, Inc. (Pinksheets: APII.PK - News) today announced it that has entered into a Letter of Intent to merge with Google Apps® reseller VizzEco, an Ontario company. Following the merger, the two companies plan to jointly create a synergistic vertical business model designed to gain maximum benefit from leveraging the respective strengths of each company to market VizzEco's licensed Google® products and service offerings to their targeted customer market, consisting primarily of small and medium-sized businesses.
VizzEco is a licensed world-wide reseller of Google® products and services, including Google Apps® and the soon to be released Google Plus for Business® (Google+4B), which will integrate social media as a service. The VizzEco business model is designed to capitalize on the trend towards use of cloud computing services (SaaS) in replacement of PC-based software by assisting small and medium-sized businesses to take advantage of the benefits offered by SAAS. VizzEco also intends to establish a network of retail outlets to generate sales and provide customer training in order to facilitate market acceptance of Google Apps® and Google+4B services.
Safe Harbor Statement
http://finance.yahoo.com/news/Action-Products-International-iw-232537771.html?x=0
.08 x 300%=.24
from positive data for its experimental Alzheimer's treatment, bapineuzumab,
http://www.cnbc.com/id/44259918
Beta-amyloid may provide a viable target for treatment of AMD
Beta-amyloid may provide a viable target for treatment of AMD 22-Aug-11 11:47 pm Research, published in the US Proceedings of the National Academy of Science (PNAS, doi/10.1073/pnas.1100901108), has demonstrated that beta-amyloid (A-beta), normally targeted in Alzheimer's disease, may also reverse retinal deposition associated with dry AMD and protect visual function. The finding could open a large new market for a number of pharmaceutical companies already in late stage clinical trials with compounds targeting beta-amyloid.
The research findings, built on previous observations that beta-amyloid (A-beta) accumulated in the drusen of AMD patients but not in those without AMD, firmly establish A-beta as a viable AMD target. Introducing antibodies against beta-amyloid (A-beta) in a mouse model of AMD showed a significant therapeutic affect and an improvement in visual acuity. One such monoclonal antibody tested was Pfizer's ponezumab (PF-04360365), currently under going Phase II tests for Alzheimer's. The research collaboration between Prof. Catherine Bowes-Rickman of the Duke Eye Center, Duke University, North Carolina, USA and Pfizer's Worldwide Research and Development group based in La Jolla, California, demonstrated that an intra-peritoneal injection of a bi-specific monoclonal antibody, capable of recognizing the C-terminus of both the A-beta 40 and A-beta 42 peptides, blocked histopathological changes of AMD and completely protected visual function in a new murine AMD model. The new AMD model over-expresses the human form of the cholesterol transport protein apolipoprotein E4 (APOE4), which causes accumulation of beta-amyloid and increases the risk of Alzheimer's disease. Feeding the animals a high cholesterol diet accelerates the pathological process.
The researchers postulated that the approach may work through a "sink effect" in which the injected mAbs do not penetrate the blood-brain barrier but rather soak up blood borne A-beta, thereby preventing it getting to the eye in the first place. Soaking it up before it gets to the eye may reduce the A-beta levels in drusen which in turn reduces the chronic activity of the complement system. In conclusion, the researchers suggest that "treatment with anti- A-beta antibodies could produce improvements in retinal function deficits observed in both early and advanced stages of AMD, especially for those patients in whom A-beta deposition is a feature of their disease. The significance of the potential impact of an early-stage AMD therapy cannot be overstated considering that AMD is the leading cause of blindness in industrialized countries and that, currently, there are no effective therapies for the dry form of the disease, which affects the vast majority of AMD patients".
http://www.euretina.org/site/euretina-br...
Good news in fight against Alzheimer's disease
There is some good news on the Alzheimer’s front. A New Jersey’s doctor’s diligence may have opened the door to a simple and accurate means of screening for the disease before any symptoms appear.
Bob Nagele, a longtime University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine researcher, has devised a test that scans for certain substances in a single drop of blood. Detection of 10 obscure antibodies signifies a patient, unknowingly, is already fighting off deadly Alzheimer’s disease.
Early detection is vital because the disease can begin infiltrating the brain a decade or more before people begin to show symptoms.
In a Times report early this month, The Star-Ledger’s Seth Augenstein explained the elegantly simple yet painstakingly exact process Dr. Nagele developed in his South Jersey lab. The breakthrough caps a decade’s work to analyze often overlooked fragments in the blood of Alzheimer‘s patients.
His test is 95 percent accurate and takes 24 hours for results — and requires just a single drop of blood. If verified by the scientific community, it could replace the current multiple-exam method that is often inexact — and takes much longer.
While Dr. Nagele and other researchers test their theories and attempt to pinpoint the exact cause, and potential cure, for Alzheimer’s, federal health officials are beginning to assemble a National Alzheimer’s Plan to combat the insidious disease.
In a series of nationwide hearings, the Alzheimer’s Association is gathering input from patients and caregivers to help shape that strategy. A new law mandates the plan to help the country prepare and respond to the swelling incidence of Alzheimer’s and its devastating effects.
Those effects are personal, as once vibrant people become helpless ghosts of themselves who can linger in blank limbo for decades after their diagnosis. The disease also affects the economy with staggering medical costs and the drain of billions of hours that caregivers devote to patients.
And, of course, as we live longer and the population continues to grow, the incidence of Alzheimer’s is increasing. There are more than 5.4 million Americans diagnosed with the disease; about 150,000 are New Jersey residents. By 2050, as many as 16 million Americans will have the disease.
Treatments to slow Alzheimer’s progression, such as a new drug from Johnson & Johnson expected to go to regulators by 2013, continue to be developed. But that pace cannot keep up the accelerating incidence of the disease.
In the time it took to read this editorial, three more Americans have developed Alzheimer’s.
Follow the Times of Trenton on Twitter.
http://www.nj.com/times-opinion/index.ssf/2011/08/post_1.html
Good news in fight against Alzheimer's disease
There is some good news on the Alzheimer’s front. A New Jersey’s doctor’s diligence may have opened the door to a simple and accurate means of screening for the disease before any symptoms appear.
Bob Nagele, a longtime University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine researcher, has devised a test that scans for certain substances in a single drop of blood. Detection of 10 obscure antibodies signifies a patient, unknowingly, is already fighting off deadly Alzheimer’s disease.
Early detection is vital because the disease can begin infiltrating the brain a decade or more before people begin to show symptoms.
In a Times report early this month, The Star-Ledger’s Seth Augenstein explained the elegantly simple yet painstakingly exact process Dr. Nagele developed in his South Jersey lab. The breakthrough caps a decade’s work to analyze often overlooked fragments in the blood of Alzheimer‘s patients.
His test is 95 percent accurate and takes 24 hours for results — and requires just a single drop of blood. If verified by the scientific community, it could replace the current multiple-exam method that is often inexact — and takes much longer.
While Dr. Nagele and other researchers test their theories and attempt to pinpoint the exact cause, and potential cure, for Alzheimer’s, federal health officials are beginning to assemble a National Alzheimer’s Plan to combat the insidious disease.
In a series of nationwide hearings, the Alzheimer’s Association is gathering input from patients and caregivers to help shape that strategy. A new law mandates the plan to help the country prepare and respond to the swelling incidence of Alzheimer’s and its devastating effects.
Those effects are personal, as once vibrant people become helpless ghosts of themselves who can linger in blank limbo for decades after their diagnosis. The disease also affects the economy with staggering medical costs and the drain of billions of hours that caregivers devote to patients.
And, of course, as we live longer and the population continues to grow, the incidence of Alzheimer’s is increasing. There are more than 5.4 million Americans diagnosed with the disease; about 150,000 are New Jersey residents. By 2050, as many as 16 million Americans will have the disease.
Treatments to slow Alzheimer’s progression, such as a new drug from Johnson & Johnson expected to go to regulators by 2013, continue to be developed. But that pace cannot keep up the accelerating incidence of the disease.
In the time it took to read this editorial, three more Americans have developed Alzheimer’s.
Follow the Times of Trenton on Twitter.
http://www.nj.com/times-opinion/index.ssf/2011/08/post_1.html
300% is only .24. If babi gets approved this will go to dollars. Someone on the ELN IV board said that PFE stopped Ponezumab. I am trying to verify that.
Do have an example of something they have cleaned up. They did not get any work in The Gulf disaster???
In your opinion what company has the most promising Alzheimer's potential drug.
No! I emailed them to ask a simple question. I just wanted to see pictures of their equipment. They have never responded.
Where in Texas? I am in Texas.
sub penny-several reverse spits
I have 3 shares that cost me 12K, you want them?
This company has done at least two reverse splits in the last year or so. I don't know why the SEC doesn't shut them down? Steeling share holders money IMO.
I have 3 shares that cost me $12,000. Anyone want them?
If babi gets approved it will go way past .51. Don't feel bad, I have 3 shares of EVXA that my cost is $12,179! RS three or four times! Plan to get it back on ILNS. Will take some time, one to two years. Babi is by far the most advanced drug for AZ at this time. Good luck and be very patient.
PWTC up 200% on news
massivegains10 what about RXPC from Friday?